{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:23:18Z","timestamp":1784809398146,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100425","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T23:25:54Z","timestamp":1646436354000},"page":"100425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials"],"prefix":"10.1016","volume":"7","author":[{"given":"E.F.","family":"Nassif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-P.","family":"Sunyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bahleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Le Pechoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2022.100425_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M","article-title":"Adriamycin chemotherapy\u2014efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule","volume":"33","author":"Benjamin","year":"1974","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100425_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100425_bib3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2022.100425_bib4","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2000.18.14.2676","volume":"18","author":"Le Cesne","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2022.100425_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000494861","article-title":"Making the best of available options for optimal sarcoma treatment","volume":"95","author":"Le Cesne","year":"2018","journal-title":"Oncology"},{"issue":"Suppl 4","key":"10.1016\/j.esmoop.2022.100425_bib6","doi-asserted-by":"crossref","first-page":"iv268","DOI":"10.1093\/annonc\/mdy321","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100425_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(15)70070-7","article-title":"Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial","volume":"16","author":"Pautier","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100425_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2019.10.028","article-title":"A\u00a0phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: a unicancer French Sarcoma Group study (LMS03 study)","volume":"25","author":"Pautier","year":"2020","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"10.1016\/j.esmoop.2022.100425_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.11505","article-title":"Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS)","volume":"38","author":"Roland","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100425_bib10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"},{"issue":"32","key":"10.1016\/j.esmoop.2022.100425_bib11","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2016.67.6684","article-title":"PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma","volume":"34","author":"Ryan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100425_bib12","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/annonc\/mdz408","article-title":"Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation","volume":"30","author":"Blay","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100425_bib13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdz170","article-title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study","volume":"30","author":"Blay","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100425_bib14","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/annonc\/mdx484","article-title":"Improved survival using specialized multidisciplinary board in sarcoma patients","volume":"28","author":"Blay","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100425_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100425_bib16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/annonc\/mdx774","article-title":"Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'","volume":"29","author":"Schoffski","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100425_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2016.02.002","article-title":"Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity","volume":"58","author":"Vlenterie","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100425_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","article-title":"Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial","volume":"20","author":"Martin-Broto","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100425_bib19","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S1470-2045(19)30319-5","article-title":"Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial","volume":"20","author":"Stacchiotti","year":"2019","journal-title":"Lancet Oncol"},{"issue":"supp 1","key":"10.1016\/j.esmoop.2022.100425_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14737140.2020.1753510","article-title":"Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype","volume":"20","author":"Martin-Broto","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100425_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100425_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s43018-020-00163-8","article-title":"Envisioning the future of precision oncology trials","volume":"2","author":"Madhavan","year":"2021","journal-title":"Nat Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100425_bib23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-019-0262-9","article-title":"Phase I trials as valid therapeutic options for patients with cancer","volume":"16","author":"Adashek","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100425_bib24","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/cncr.26413","article-title":"Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center","volume":"118","author":"Garrido-Laguna","year":"2012","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.esmoop.2022.100425_bib25","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2008.19.5081","article-title":"Prospective validation of a prognostic score to improve patient selection for oncology phase I trials","volume":"27","author":"Arkenau","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100425_bib26","series-title":"Encyclopedia of Cancer","article-title":"(eds) CTCAE","author":"Schwab","year":"2011"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100425_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100425_bib28","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/cncr.25538","article-title":"Trends in survival for patients with metastatic soft-tissue sarcoma","volume":"117","author":"Italiano","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100425_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","article-title":"Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study","volume":"15","author":"Savina","year":"2017","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100425_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00280-010-1484-9","article-title":"Clinical benefit of early phase clinical trial participation for advanced sarcoma patients","volume":"68","author":"Jones","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100425_bib31","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/annonc\/mdu108","article-title":"Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European phase I database","volume":"25","author":"Cassier","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100425_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-017-0301-y","article-title":"Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials","volume":"5","author":"Groisberg","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100425_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrclinonc.2015.194","article-title":"The changing landscape of phase I trials in oncology","volume":"13","author":"Wong","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100425_bib34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/annonc\/mdx795","article-title":"Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding","volume":"29","author":"Yan","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100425_bib35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41571-018-0102-3","article-title":"Accelerating anticancer drug development - opportunities and trade-offs","volume":"15","author":"Nass","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"10043","key":"10.1016\/j.esmoop.2022.100425_bib36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:39Z","timestamp":1761855999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000461"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100425","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100425"}}